» Articles » PMID: 38509101

Open-label Placebos Enhance Test Performance and Reduce Anxiety in Learner Drivers: a Randomized Controlled Trial

Overview
Journal Sci Rep
Specialty Science
Date 2024 Mar 21
PMID 38509101
Authors
Affiliations
Soon will be listed here.
Abstract

Passing the driving school test can be very challenging, especially in big cities, where up to 52% of all students fail this test. Consequently, many learner drivers experience stress and anxiety. For some learner drivers these feelings can be extreme and negatively affect the performance in the driving test. Different strategies to face anxiety and stress are known, including, for example, psychological or pharmacological approaches and even placebo pills. Recent intriguing findings have also demonstrated that placebos without deception, so-called open-label placebos, successfully reduce anxiety. Here we aimed to test effects of this novel treatment for learner drivers. We investigated whether open-label placebos affect test performance and feelings of anxiety in learner drivers. Sixty-eight healthy participants (mean age 21.94 years, 26 females) were randomized into two groups. The open-label placebo group received placebo pills two weeks before the driving test (two pills each day). The control group received no treatment. Results revealed that the open-label placebo group experienced significantly less anxiety than the control group before the test (measured with the State-Trait-Anxiety-Inventory, STAI-S, and the German Test Anxiety Inventory, PAF). Moreover, in the open-label placebo group less learner drivers failed the driving test (29.41% vs. 52.95%). The results suggest that open-label placebos may provide an ethical unproblematic way to experience less anxiety and might also enhance the probability to pass the driving test. We discuss possible mechanisms of open-label placebos and limitations of our findings.

References
1.
Schaefer M, Zimmermann K, Enck P . A randomized controlled trial of effects of open-label placebo compared to double-blind placebo and treatment-as-usual on symptoms of allergic rhinitis. Sci Rep. 2023; 13(1):8372. PMC: 10206347. DOI: 10.1038/s41598-023-34790-9. View

2.
Guevarra D, Moser J, Wager T, Kross E . Placebos without deception reduce self-report and neural measures of emotional distress. Nat Commun. 2020; 11(1):3785. PMC: 7391658. DOI: 10.1038/s41467-020-17654-y. View

3.
Kaptchuk T, Miller F . Open label placebo: can honestly prescribed placebos evoke meaningful therapeutic benefits?. BMJ. 2018; 363:k3889. PMC: 6889847. DOI: 10.1136/bmj.k3889. View

4.
Darragh M, Yow B, Kieser A, Booth R, Kydd R, Consedine N . A take-home placebo treatment can reduce stress, anxiety and symptoms of depression in a non-patient population. Aust N Z J Psychiatry. 2015; 50(9):858-65. DOI: 10.1177/0004867415621390. View

5.
von Wernsdorff M, Loef M, Tuschen-Caffier B, Schmidt S . Effects of open-label placebos in clinical trials: a systematic review and meta-analysis. Sci Rep. 2021; 11(1):3855. PMC: 7887232. DOI: 10.1038/s41598-021-83148-6. View